developer@wearewoodruff.com

Kansas City, Mo. — April 2, 2025 — As part of its commitment to enhance animal health, Felixvet has successfully launched Carprofen Soft Chewable Tablets, now available through animal health distributors. Felixvet, Inc., a generic companion animal pharmaceutical manufacturer based in Ireland, established its North American headquarters in Kansas City, Missouri, in 2023.

“We are excited to announce the launch of our fifth carprofen product offering in the U.S. market,” said Vince Palasota, President of North America at Felixvet. “This development marks a significant step forward in providing quality, affordable healthcare solutions for pets without sacrificing efficacy, safety or reliability.”

Felixvet is leading the animal health market by introducing Carprofen Soft Chewable Tablets to its portfolio of carprofen products. This addition offers veterinarians five different forms of carprofen, each specifically designed to meet the diverse needs of their customers.

“We are committed to introducing additional products that will help us become one of the leading companion animal generic drug companies globally,” states Palasota.

Carprofen Soft Chewable Tablets provide the same therapeutic benefits as other branded carprofen medications, but the new beef flavored Felixvet Soft Carprofen Chewable Tablets offer a state of the art, unique soft chewable tablet compared to the hard chewable tablet pioneer, RIMADYL^®. They are easy to administer orally due to the palatable beef flavor. Felixvet’s Soft Chewable technology is based on traditional compression technology without the constraints imposed by current production processes such as extrusion or molding.

A nonsteroidal anti-inflammatory, Carprofen Soft Chewable Tablets relieve pain and inflammation associated with osteoarthritis. The tablets are therapeutically equivalent to the pioneer drug, RIMADYL^®, with the same safety and efficacy. Available in three strengths, 25, 75 and 100 mg, each tablet is scored for easy and accurate dosing.

For more information, visit Felixvet.com or info@felixvetus.com.

About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Kansas City, Mo. — March 18, 2025 — Felixvet, Inc., an Ireland-based generic companion animal pharmaceutical manufacturer, established its North American headquarters in Kansas City, Mo., in 2023, is pleased to announce the addition of Matthew Maggio and Michael Morelli as Directors of Corporate Accounts for North America. In their new roles, Maggio and Morelli will execute strategic sales plans, foster long-term partnerships, collaborate with distributor partners and drive business growth through creative marketing solutions.

Matthew Maggio has nearly two decades of experience leading high-performing teams in the pharmaceutical industry, including MWI Animal Health, Elanco and Boehringer Ingelheim Vetmedica, Inc.

Before joining Felixvet, Maggio launched his career in sales and quickly rose through the ranks to become a top-producing salesperson and account manager. Throughout his career, he has consistently excelled in competitive markets, leveraging his extensive technical knowledge in animal immunology, pharmaceuticals and product marketing to drive success.

Michael Morelli brings a wealth of experience, having previously served as a National Account Manager and Sales Director, where he successfully drove large-scale account growth and managed high-performing teams. Morelli has honed his leadership and strategic sales skills, overseen regional operations and cultivating strong customer relationships.

Before joining Felixvet, Morelli held leadership roles at Terumo Medical Corporation, IQVIA and Takeda Pharmaceuticals North America, where he successfully developed and motivated high-performing teams. Throughout his career, he has worked closely with animal health distributors and veterinarians, forging strategic partnerships to drive business growth and innovation.

“We are very pleased to have both Matthew Maggio and Michael Morelli join the team at Felixvet. Together, they bring over 40 years of experience in pharmaceutical industry sales and have a proven track record of success,” said Vince Palasota, President of Felixvet North America. “Their expertise will be instrumental in helping us achieve our growth objectives. With a wealth of experience in sales management and team leadership, they will help us on our mission to advance veterinary care by offering straight generics, value-added products, and novel solutions.”

For more information, visit Felixvet.com or info@felixvetus.com.

About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bio-equivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in the North American markets, upon approval by the Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Author: developer@wearewoodruff.com

Felixvet Launches Carprofen Soft Chewable Tablets

Felixvet Announces New Hires to Lead Sales